SAN DIEGO—(BUSINESS WIRE)—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the BIO CEO & Investor
Conference 2009 on Tuesday, February 10, 2009, at 10:00 a.m. Eastern
Time at The Waldorf=Astoria Hotel in New York City.
A live webcast of ACADIA’s presentation will be accessible on the
company’s website, www.acadia-pharm.com,
under the investors section and an archived recording will be available
on the website through February 24, 2009.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for
central nervous system disorders. ACADIA is focused on developing a
portfolio of its four most advanced product candidates, including
pimavanserin in Phase III for Parkinson’s disease psychosis, a product
candidate in Phase II for chronic pain and a product candidate in Phase
I for glaucoma, both in collaboration with Allergan, and ACP-106 in
IND-track development. All of the product candidates in ACADIA’s
pipeline emanate from discoveries made using its proprietary drug
discovery platform. ACADIA maintains a website at www.acadia-pharm.com
to which ACADIA regularly posts copies of its press releases as well as
additional information and through which interested parties can
subscribe to receive email alerts.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor
Relations
Thomas H. Aasen, Vice President and Chief
Financial Officer
858-558-2871